Drug intelligence / Profile preview

MGT-2202

Development stage: Preclinical
Lead developer: MiGenTra
Administration: Parenteral

Overview

MGT-2202 is an investigational oncology therapeutic candidate developed by MiGenTra, a joint venture between Minapharm and ProBioGen. The drug is part of MiGenTra's pipeline focused on expanding access to biologics and biosimilars in Africa and the Middle East. While it is explicitly categorized within the oncology therapeutic area on the sponsor's pipeline page, specific details regarding its molecular target, mechanism of action, and current clinical phase have not been publicly disclosed. MiGenTra utilizes advanced manufacturing technologies to develop high-quality biologics for regional markets.

Beyond the preview

Go deeper on MGT-2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGT-2202.

Explore the full profile